*This is a research project being conducted by the NIH/NHLBI-supported Pediatric Heart Network to study the dissemination of results of an NIH-sponsored clinical trial. You are invited to participate because you have been identified as a pediatric cardiovascular medicine specialist.

This brief survey should take no more than 5 minutes to complete. The results of this study will be used for scholarly purposes only with the goal of improving care of children with complex congenital heart disease.

Your responses will be confidential and the survey does not collect personally identifying information. SurveyMonkey will block your email address so responses cannot be linked with your name. SSL encryption will be used to protect data transmission. All study data are stored on database servers, with access controlled by extensive security features.

Participation in the study is voluntary and you can stop it with no penalty at any time by clicking an 'Exit this survey' button present on each page of the survey (or by simply closing the browser). The responses you've provided before exiting from the survey will be saved.

Should you have any questions about this study, please contact the principal investigator, Dr. Victor Zak at the New England Research Institutes at (800) 775-6374, extension 233. If you have any questions regarding your rights as a research subject, please contact Ms. Nancy Gee, MPH, Institutional Review Board Administrator at the New England Research Institutes at (800) 775-6374, extension 249

ELECTRONIC CONSENT: Please select your choice below.

0	I have read the above	information, and	I voluntarily agree	to participate in	this survey
---	-----------------------	------------------	---------------------	-------------------	-------------

I do not wish to participate in this survey

*	1. How would you describe yourself professionally (please select one answer)?
0	Pediatric cardiologist
0	Pediatric intensivist
0	Pediatric cardiac surgeon
0	Advanced practice nurse or nurse practitioner (with prescribing privileges)
0	Medical professional not involved in patient care
0	Prefer not to respond
0	Other (please specify)

C 0 C 1-5 C 5-10 C 11-15 C > 15 C Prefer not to respond Comments	*2. How many single ventricle infants do you care for in a year (on average, over last 5 years)?	
 6-10 11-15 >15 Prefer not to respond 	© 0	
11-15>15Prefer not to respond	O 1-5	
>15Prefer not to respond	© 6-10	
C Prefer not to respond	C 11-15	
	C >15	
Comments	C Prefer not to respond	
	Comments	

*3. Over the last 3 years, did you change your prescription practice for angiotensin converting enzyme (ACE) inhibition therapy for single ventricle (SV) infants < 14 months of age?					
C Yes, overall I currently prescribe ACE inhibition therapy for SV infants < 14 months of age more frequently					
O Yes, overall I currently prescribe ACE inhibition therapy for SV infants < 14 months of age less frequently					
O No, I don't normally prescribe cardiac meds					
O No, overall there is no change in my prescription practice of ACE inhibition therapy for SV infants < 14 months of age					
O Not sure					
C Prefer not to respond					
Other (please specify)					

*4. At the present time, how frequently do you prescribe ACE inhibition therapy to single
ventricle infants < 14 months of age? C Almost always (except for the cases with contraindications)
Selectively
○ Almost never
O Never
C Prefer not to respond
Comments

ingle ventricle illiants > 17 illontiis	of age? (Please select all th	at apply)
	TO PREVENT	TO TREAT
ystemic ventricular dysfunction		
trioventricular valve regurgitation		
por growth		
emilunar valve regurgitation		
ypertension		
refer not to respond		
her (please specify)		

*6. Have results of the Pediatric Heart Network (PHN) sponsored trial of ACE inhibition in
infants with single ventricle (ISV trial) been helpful to you in making treatment decisions?
Yes, I've changed my treatment decisions as a result of the trial findings
Yes, I am more confident now in my treatment decisions as a result of the trial findings, though they didn't change
No, I am not familiar with the results of this trial
No, I am familiar with the trial's results, but they didn't affect my treatment decisions
C Prefer not to respond
Comments

*7. In the past, before learning about the ISV trial findings, how frequently did you			
prescribe ACE inhibition therapy to single ventricle infants < 14 months of age? C Almost always (except for the cases with contraindications)			
Almost always (except for the cases with contraindications)Selectively			
C Almost never			
C In the past I didn't prescribe cardiac meds			
C Never			
C Prefer not to respond			
Comments			

elect all that apply)	TO PREVENT	TO TREAT
Systemic ventricular dysfunction		
atrioventricular valve regurgitation		
Poor growth		
Semilunar valve regurgitation		
lypertension		
Prefer not to respond		
ther (please specify)		

I read a brief description elsewhere Colleagues told me about the results I was actively involved in the conduct of the trial I was somewhat involved in the execution of the trial Other (please specify) TO. Please check any/all of the following statements about the ISV trial: agree disagree not sure lial was well designed C C C attents in the study are similar to the patients I care for in my practice C C andings of the trial were properly interpreted C C Conditionary endpoint was relevant C C Conditionary endpoint was too low C C C C Conditionary endpoint was too low C C C C Conditionary endpoint was too low C C C C Conditionary endpoint was too low C C C C Conditionary endpoint was too low C C C C Conditionary endpoint was too low C C C C C C C C C C C C C C C	I heard or read about the presentation at the American Heart Association Med	eting		
Colleagues told me about the results I was actively involved in the conduct of the trial Prefer not to respond Other (please specify) Calculate the study are similar to the patients I care for in my practice originary endpoint was relevant condings of the trial were properly interpreted one of ACE inhibition was too low or popul rate was too ligh condings of was too small Colleagues told me about the trial I was actively involved in the execution of the trial I was somewhat involved in the execution of the trial I was somewhat involved in the execution of the trial I was somewhat involved in the execution of the trial Prefer not to respond Colleagues Specify) Colleagues Specify I was somewhat involved in the execution of the trial Agree disagree not sure agree disagree not sure on colleagues old Agree not sure agree disagree not sure on colleagues or colleagues	I read the publication			
I was actively involved in the conduct of the trial I was somewhat involved in the execution of the trial Prefer not to respond Other (please specify) The specific of the following statements about the ISV trial: agree disagree not sure rial was well designed C C C attents in the study are similar to the patients I care for in my practice C C Indings of the trial were properly interpreted C C C Indings of the trial were properly interpreted C C C Indings of ACE inhibition was too low C C Indings to short C C C C Indings to short C C C Indings to short C C C C C C Indings to short C C C C C C Inding	I read a brief description elsewhere			
I was somewhat involved in the execution of the trial Prefer not to respond Other (please specify) ***TO. Please check any/all of the following statements about the ISV trial: ***Tagee disagree not sure rial was well designed C C C C C C C C C C C C C C C C C C C	Colleagues told me about the results			
Prefer not to respond Other (please specify) F10. Please check any/all of the following statements about the ISV trial: agree disagree not sure rial was well designed C C C C C attents in the study are similar to the patients I care for in my practice C C C C C c c c c C C C C C C C C C C	I was actively involved in the conduct of the trial			
Other (please specify) F10. Please check any/all of the following statements about the ISV trial: agree disagree not sure rial was well designed C C C attents in the study are similar to the patients I care for in my practice C C rimary endpoint was relevant C C ondings of the trial were properly interpreted C C onse of ACE inhibition was too low C C onsent rate was too short C C onsent rate was too high C C ample size was too small refer not to respond C C C onterpretation of the trial was too small one of C C C one of C C one of C C one of C C C one o	I was somewhat involved in the execution of the trial			
Fig. 10. Please check any/all of the following statements about the ISV trial: agree disagree not sure rial was well designed C C C C C C C C C C C C C C C C C C C	Prefer not to respond			
F10. Please check any/all of the following statements about the ISV trial: agree disagree not sure rial was well designed C C C C C attents in the study are similar to the patients I care for in my practice C C C C C C C C C C C C C C C C C C C	Other (please specify)			
rial was well designed C C C C C C C C C C C C C C C C C C C	//			
rial was well designed C C C attents in the study are similar to the patients I care for in my practice C C C crimary endpoint was relevant C C C crimary endpoint was relevant C C C condings of the trial were properly interpreted C C C conse of ACE inhibition was too low C C C consent rate was too short C C C consent rate was too low C C C consent rate was too low C C C consent rate was too high C C C consent rate was too small	10. Please check any/all of the following statemen			
atients in the study are similar to the patients I care for in my practice C C C C C C C C C C C C C C C C C C	rial was well designed		_	
rimary endpoint was relevant Indings of the trial were properly interpreted	atients in the study are similar to the patients I care for in my practice			
ose of ACE inhibition was too low C C C C C C C C C C C C C C C C C C	rimary endpoint was relevant	O	\odot	0
collow-up was too short consent rate was too low cop out rate was too high comple size was too small completed on the first of the	indings of the trial were properly interpreted	0	0	0
onsent rate was too low rop out rate was too high complesize was too small refer not to respond Complete Co	ose of ACE inhibition was too low	O	0	0
rop out rate was too high ample size was too small refer not to respond C C C C C C	ollow-up was too short	0	0	0
ample size was too small refer not to respond C C C C C C	onsent rate was too low			
refer not to respond	rop out rate was too high			
ner (please specify)		0	0	0
	ner (please specify)			

	11. Have you ever practiced at a Pediatric Heart Network (PHN) clinical site (main or
	xiliary)?
0	Yes
0	No
0	Don't know
0	Prefer not to respond
*	12. How many years have you been practicing your specialty?
0	Currently in training
0	< 5 years after training
0	5 to 9 years after training
0	10 to 20 years after training
0	> 20 years after training
0	Prefer not to respond
Con	nments
	Northeastern USA Southeastern USA Mid-West USA Northwestern USA Southwestern USA Canada Prefer not to respond Other (please specify)
** o	14. How would you describe your clinical practice? Academic/University based Non-university private practice or salaried employee of a hospital
0	Non-university based practice with a close affiliation with an academic institution (i.e. adjunct academic appointment)
0	Prefer not to respond
0	
~	Other (please specify)

*	15. How do you commonly learn about results of clinical research in your field? (Please
	lect all that apply)
	Presentation at a national meeting
	Publication in a peer-reviewed journal
	Website of professional organizations
	Newsletters from professional organizations
	Colleagues
	Prefer not to respond
	Other (please specify)
*	What is your gender?
0	
0	Male

Thanks for your time.